FDA guidance on clinical trial data disclosure falls short, while noncompliance remains high

October 9, 2018

As seen on Outsourcing-Pharma.com - Posted Oct. 8, 2018 - Original Article

 By Melissa Fassbender | The recent FDA guidance ties penalties for not disclosing clinical trial results to formal inspections – falling short of the public expectation that such data should be readily available, says industry expert.


Continued on Outsourcing Pharma

Previous Article
Web-based service targets clinical trial sponsors
Web-based service targets clinical trial sponsors

Next Article
TrialScope and More: News from September 2018
TrialScope and More: News from September 2018